human embryonic dopamine neurons

Human embryonic dopamine neurons refer to a cell therapy approach for Parkinson's disease involving the transplantation of dopamine-producing nerve cells derived from the ventral mesencephalon of human embryos (typically 6 to 9 weeks of gestational age). The therapeutic rationale is based on cell replacement: once transplanted into the dopamine-depleted putamen, these neurons can survive, integrate into the host brain, and release endogenous dopamine. Major double-blind, sham-controlled clinical trials in the late 1990s and early 2000s demonstrated that while these grafts could survive and provide long-term functional benefits in some patients (particularly younger ones), the overall results were inconsistent, and many patients developed graft-induced dyskinesias (GIDs). Due to ethical concerns regarding the source of tissue, logistical challenges in obtaining consistent donor material, and these clinical complications, the use of primary fetal tissue has largely been superseded by standardized, stem cell-derived (hESC or iPSC) dopamine progenitor therapies.

Other names

human embryonic ventral mesencephalic tissuehuman fetal mesencephalic tissuehuman embryonic DA neuronsventral mesencephalic dopamine neurons